錦欣生殖(1951.HK)大漲近10% 再創歷史新高
格隆匯2月18日丨入選了格隆匯2021年“下注中國”十大核心潛力資產名單的錦欣生殖(1951.HK)拉昇走強,現漲9.8%,報22.4港元,再創歷史新高,成交額1.35億港元,總市值超560億港元。近期,錦欣生殖公佈配股籌資計劃,擬以15.85港元配售8000萬股,淨額12.53億港元。公司表示,儘管COVID-19疫情給整體ARS行業帶來一定挑戰,但也為公司推進併購及增長戰略提供了良好的窗口,從而把握機會加快國內擴張及國際佈局。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.